|
| |
LorantisLorantis is discovering and developing breakthrough products for the selective treatment of immunological and inflammatory diseases based on immune regulation: the induction of antigen-specific tolerance.
Current therapies for immunological and inflammatory diseases either relieve only the symptoms or induce non-specific suppression of the immune system. This can lead to severe infection and drug-related toxicity. Lorantis is addressing unmet clinical needs in immunological diseases by developing selective treatments that target pathological responses, but don’t block normal responses or adversely affect non-immune organs. This selectivity is being achieved by:
New drugs for targets in the immune system with improved specificity for pathological responses.
Delivery mechanisms with improved selectivity for cells of the immune system.
Lorantis' lead products are derived from new biochemical signalling pathways that regulate specific actions of T-cells which control immune responses. These and other related discoveries will allow Lorantis to build a portfolio of novel drugs, which will treat the root causes of several immunological diseases, including allergy, asthma, autoimmune diseases and transplant regulation.
| Contact Details: |
| 317 Cambridge Science Park |
| Cambridge |
| |
| CB4 OWG |
| United Kingdom |
| Tel: | 01223 702 500 |
| Fax: | 01223 702599 |
| Email: | mark.bodmer@lorantis.com |
| WWW: | www.lorantis.com/
|
|
Loading...
|
Recent Publications by Lorantis: |  |
RNA interference.
Since its initial description as a neurogenic locus in Drosophila, the... | 9th April, 2008
| Lorantis Ltd, 410 Cambridge Science Park, Cambridge, CB4 0PE, UK.
| Pharmacogenomics. 2005 Jan;6(1):13-6.
DOI Direct Link |
Small interfering RNA-mediated knockdown of notch ligands in primary CD4+ T cells and dendritic cells enhances cytokine production.
The key interaction in the adaptive immune system's response to pathogenic... | 19th August, 2006
| Lorantis Ltd., Cambridge, United Kingdom.
| J Immunol. 2006 Jul 15;177(2):885-95.
|
Notch: a unique therapeutic target for immunomodulation.
Under normal circumstances, the adaptive immune response to either self or... | 2nd June, 2006
| Lorantis Ltd, Cambridge Science Park, Cambridge, CB4 0PE, UK.
| Expert Opin Ther Targets. 2005 Apr;9(2):395-410.
DOI Direct Link |
Cellular Notch responsiveness is defined by phosphoinositide 3-kinase-dependent signals.
BACKGROUND: Notch plays a wide-ranging role in controlling cell fate,... | 4th May, 2006
| Lorantis Ltd.,
| BMC Cell Biol. 2006 Feb 28;7:10.
DOI Direct Link |
Modulation of the notch pathway for immunotherapy.
Since its initial description as a neurogenic locus in Drosophila, the... | 21st May, 2005
| Lorantis
| Curr Opin Mol Ther. 2005 Feb;7(1):56-61.
|
→View more Lorantis research publications. |
Press Releases on Lorantis:
|
 |
| Abingworth life sciences venture capital group appoints Michelle Doig |
1st February, 2003 |
Abingworth |
Abingworth life sciences venture capital group appoints Michelle Doig
London, UK, 17th February 2003 - Abingworth Management, the life sciences venture capital group, has
|
| Dr John Padfield Appointed to Board of Akubio as Chairman |
1st December, 2002 |
Akubio |
Dr
John Padfield Appointed to Board of Akubio as Chairman
Cambridge,
UK, April 30th 2003….
Akubio Ltd, the acoustic detection technology company,
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 363 times since April 2007, the link to the organisation's website has been followed 77 times Recent Search Terms used to find this page: lorantis | Lorantis Ltd Technology | lorantis | is lorantis uk still in business | lorantis | lorantis ltd | lorantis | lorantis | lorantis | lorantis | . Search for more companies in Cambridge Search for more companies in This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Lorantis |
